Paid fellowship is offered
Oklahoma college students are invited to apply for a paid, 10-week fellowship this summer at an entrepreneurial company in the Oklahoma City or Tulsa area. Applications for the 2013 i2E Fellows program are being accepted through March 15. Undergraduate and graduate students are eligible. Fellows will earn $6,000 while working full-time on projects designed specifically for their skill sets at i2E client companies. The fellowships begin June 3. Now in its fifth year, the i2E Fellows program is offered in Oklahoma City with support from the federal Economic Development Administration, the Greater Oklahoma City Chamber, the Oklahoma Business Roundtable, the city of Oklahoma City, the Oklahoma Medical Research Foundation and the Presbyterian Health Foundation. Support in Tulsa for the program is provided by the EDA, the Oklahoma Center for the Advancement of Science and Technology and the Oklahoma Business Roundtable. A total of 31 college students have served as previous i2E Fellows, and many have used the fellowship to launch their careers with entrepreneurial companies or with their own startup endeavor. Information about the i2E Fellows program can be accessed at www.i2EFellows.com or by contacting Casey Harness, i2E Fellows Program Director, at 813-2425 or charness@i2E.org.
Sensulin wins science awards
Oklahoma City-based Sensulin, LLC, a diabetes-focused biopharmaceutical company, received the 2013 Michael E. DeBakey Life Science Award at the recent second annual Texas Life Science Venture Forum in Houston. The DeBakey award is presented to the “undiscovered life science company with the highest potential to commercialize an important product.” Sensulin also received the Rice Alliance Most Promising Life Science Technology at the Houston event. Sensulin is developing a 24-hour glucose responsive insulin that would provide a patient's entire daily need via a single dose. The technology could eliminate the need for separate basal and prandial insulin injections and profoundly improve the standard of care for type 1 and type 2 diabetes patients. “The goal of our technology is to give those with diabetes a chance at a normal life,” said Mike Moradi, Sensulin's co-founder and CEO. “I have a vast family history of diabetes and this technology is particularly important to me.”